Antonios Katsianis, Emmanouil Petrou, Anna Kostopoulou and George Theodorakis Pages 9 - 13 ( 5 )
Novel oral anticoagulants (NOACs) have been developed as alternatives for vitamin K antagonists (VKAs) for the prevention of thromboembolic events in patients with a variety of medical conditions. In this review, we summarize the current data on NOACs safety and efficacy compared to VKAs and in specific patients’ groups including heart valve replacement, venous thromboembolism, advanced renal failure and the elderly.
Efficacy, novel oral anticoagulants, safety, vitamin K antagonists.
Division of Cardiology, Onassis Cardiac Surgery Center, 356 Syggrou Ave., GR-17674, Athens, Greece.